Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP), has provided an update on the status of its medicinal chemistry program being conducted by ChemDiv Inc., for the optimization of its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02. These compounds are small molecules and consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6. They were identified using Regen’s patented screening methodology and unique chemical libraries. 

Leave a Reply

Your email address will not be published.